In the cancer therapeutics field, a unique kind of cancer immunotherapy known as the ‘CAR T cell therapy’ has brought a transformation in the healthcare sector by Carl June. This type of individualized form of cancer intervention procedure has shown the potential for curing the blood cancer along with other cancer types and to some extent even solid tumors.
The immunotherapy or the CART T cell therapy mainly works with the immunity system of the patient unlike other chemotherapies and conventional radiotherapies. It helps in the eradication of the germ cells which causes cancer from its source. In this case, the T cells, a type of white blood cells, gets removed from the blood of the patient, followed by the addition of a receptor that is known as CAR T cell or “Chimeric Antigen Receptor” T Cell. These T cells are then engineered into millions of T cells for re-introducing them inside the patient’s body. These CAR T cells that are genetically harvested kill the myeloma cells. In case of the B-cell acute lymphoblastic leukemia (B-ALL), the CD19 CAR T cells have shown extraordinary remission properties.
The chimeric antigen receptor or the CAR T cell is a type of antibody that is induced with the modular fusion protein along with having an extracellular binding domain. Because of this quality, the CAR T cell therapy is now an indispensable source for treating and guarding against the recurrence of blood cancer or any other carcinogenic cases.
In the cancer therapeutics field, the CAR T cell therapy is considered to be a boon and has been adopted by many healthcare centers because of which the market is expected to augment in the upcoming years. Kite Pharma Inc., Novartis International AG, and Juno Therapeutics are some of the major industry players in the global CAR T cell therapy market. Currently, the CD 19 antigen is considered to be the most successful targeted antigen known for treating acute lymphoblastic leukemia (ALL). Clinical trials are being conducted to curb the risk of acute myeloid leukemia and solid tumors by using CAR T cell therapy.
Growing cases of cancer and other technological advancements are helping in the growth of the global CAR T cell therapy market. This is also creating growth opportunities for the existing and the new industry players. However, the long process of the clinical trials along with higher rates of therapy packages is hampering the growth of the market.
The global CAR T cell therapy market has been characterized on the basis of treatment, targeted antigen, and by geographical demand. The targeted segment of the global CAR T cell therapy market includesHER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO, and EGFRvIII. The Treatment type section of the market includes chronic lymphocytic leukemia (CLL), a non-Hodgkin lymphoma (NHL), multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), pancreatic cancer, breast cancer, colon cancer, neuroblastoma (NB), and hepatocellular carcinoma (HCC). In this case, the acute lymphoblastic leukemia group is controlling the other disease segment.
Geographically, the global CAR T cell therapy market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa. Amongst all these regions, the North American region holds the largest market share in the global CAR T cell therapy market owing to the increasing number of blood cancer patients along with the rising scientific researches in the same field. Kite PharmaInc. and Novartis AG has already applied for the FDA and BLA (Biologics License Application) for the US region. The Asia Pacific region is projected to witness the highest CAGR in terms of its growth during the forecast period 2017-2025.
The report also includes the detailed company profiles of the key industry players of the global CAR T cell therapy market. the prominent industry players include companies like Kite Pharma Inc., Novartis International AG, Juno Therapeutics, Bellicum Pharmaceuticals Inc. Cellectis, and Celgene Corporation among others.
The Middle East and Africa